current
caus
sever
acut
respiratori
syndrom
coronaviru
wide
spread
around
world
nevertheless
far
exist
specif
antivir
drug
treatment
diseas
pose
great
challeng
control
contain
viru
report
research
find
invad
host
cell
via
novel
rout
protein
sp
sp
bound
receptor
host
cell
therebi
mediat
viral
invas
research
confirm
find
first
vitro
antivir
test
indic
meplazumab
human
antibodi
significantli
inhibit
virus
invad
host
cell
ec
ic
second
valid
interact
sp
affin
constant
coimmunoprecipit
elisa
also
confirm
bind
two
protein
final
local
sp
observ
infect
vero
cell
immunoelectron
microscop
therefor
discoveri
new
rout
invad
host
cell
provid
critic
target
develop
specif
antivir
drug
treatment
therefor
intens
research
urgent
need
elucid
invas
mechan
therebi
provid
potenti
target
develop
specif
antivir
drug
report
cov
nonseg
posit
sens
rna
virus
primarili
caus
enzoot
infect
bird
mammal
demonstr
strong
lethal
human
virus
known
four
structur
protein
includ
e
n
protein
primari
determin
cov
tropism
protein
bind
membran
receptor
host
cell
mediat
viral
cellular
membran
fusion
angiotensinconvert
enzym
homologu
ace
one
import
receptor
cell
membran
host
cell
interact
sp
contribut
sarscov
invas
host
cell
interestingli
structur
sp
highli
similar
sarscov
sp
sp
bind
higher
affin
sarscov
sp
indic
stronger
abil
invad
host
cell
addit
receptor
sp
bind
host
cell
membran
remain
unclear
also
known
basigin
emmprin
transmembran
glycoprotein
belong
immunoglobulin
superfamili
involv
tumor
develop
plasmodium
invas
viru
infect
previou
research
show
play
function
role
facilit
sarscov
invas
host
cell
high
bind
rate
cell
inhibitori
effect
sarscov
research
affirm
import
viru
invas
host
cell
owe
similar
characterist
sarscov
conduct
present
studi
investig
possibl
function
invas
host
cell
studi
report
invad
host
cell
via
novel
rout
meplazumab
human
antibodi
could
competit
inhibit
bind
sp
prevent
virus
invad
host
cell
provid
potenti
target
develop
antivir
drug
antivir
test
perform
investig
possibl
function
invas
host
cell
vero
cell
cultur
plate
vero
cell
block
meplazumab
cell
infect
cell
damag
vero
viral
load
detect
crystal
violet
stain
quantit
pcr
respect
compar
control
group
inhibitori
rate
virus
significantli
increas
group
dosedepend
manner
concentr
maxim
effect
ec
figur
half
maxim
inhibitori
concentr
ic
figur
result
show
block
host
cell
inhibitori
effect
suggest
essenti
role
facilit
invas
host
cell
close
associ
invas
host
cell
sp
bind
cellular
receptor
mediat
infect
host
cell
lead
question
whether
authorfund
right
reserv
reus
allow
without
permiss
copyright
holder
preprint
peerreview
http
doi
biorxiv
preprint
relationship
sp
affect
invas
therefor
interact
assay
conduct
clarifi
interact
two
protein
surfac
plasmon
reson
spr
assay
confirm
interact
sp
rbd
affin
constant
figur
coip
assay
antisp
antibodi
antibodi
use
antibodi
immobil
respect
migg
rigg
select
neg
control
mixtur
hissp
rbd
ad
group
ip
elut
protein
detect
western
blot
result
show
interact
sp
rbd
consist
spr
assay
figur
addit
interact
rbd
also
confirm
elisa
assay
figur
meanwhil
competit
inhibit
assay
show
meplazumab
could
competit
inhibit
bind
sp
ic
figur
result
confirm
interact
sp
indic
novel
potenti
rout
invad
host
cell
determin
local
sp
process
viral
infect
vero
cell
infect
observ
immuneelectron
microscop
trace
nm
nm
sp
gold
colloidlabel
antibodi
found
two
protein
mainli
present
viral
inclus
bodi
vero
cell
figur
c
result
reinforc
find
interact
enhanc
viral
invas
host
cell
emerg
rapid
spread
across
world
trigger
global
health
emerg
patient
show
abnorm
find
chest
comput
tomographi
along
common
symptom
includ
cough
fever
fatigu
middleag
elderli
patient
underli
comorbid
suscept
respiratori
failur
may
poorer
prognosi
patholog
featur
patient
similar
patient
sar
mer
infect
howev
contagi
sar
mer
therefor
urgent
develop
specif
antivir
drug
known
wide
recogn
essenti
receptor
viru
invas
viral
replic
specif
inhibit
antibodi
howev
wide
distribut
varieti
tissu
especi
heart
kidney
test
play
profound
role
control
blood
pressur
prevent
heart
failur
kidney
injuri
lung
diseas
loss
enhanc
vascular
permeabl
lung
edema
activ
reninangiotensin
system
contribut
pathogenesi
sever
lung
injuri
therefor
treatment
target
may
neg
effect
protect
role
studi
identifi
novel
receptor
sp
interact
facilit
viral
invas
host
cell
mention
earlier
highli
express
tumor
tissu
inflam
tissu
pathogen
infect
cell
lead
low
crossreact
normal
cell
meanwhil
meplazumab
human
antibodi
could
effect
inhibit
virus
invad
host
cell
block
previou
research
develop
origin
antibodi
drug
metuximab
metuzumab
meplazumab
exhibit
sound
safeti
preclin
research
clinic
administr
therefor
target
drug
safe
reliabl
applic
receptorblock
drug
block
viru
invad
host
cell
without
affect
viru
variat
authorfund
right
reserv
reus
allow
without
permiss
copyright
holder
preprint
peerreview
http
doi
biorxiv
preprint
gener
studi
report
novel
receptor
sp
rout
facilit
invas
host
cell
therefor
rout
provid
novel
target
good
druggabl
specif
antivir
drug
develop
treatment
cell
line
vero
test
authent
use
short
tandem
repeat
dna
profil
beij
microread
genet
co
ltd
beij
china
cultur
co
dmem
rpmi
medium
supplement
fetal
bovin
serum
penicillinstreptomycin
lglutamin
spr
analysi
perform
biacor
system
biacor
produc
laboratori
fix
surfac
sensor
chip
ge
healthcar
bioscienc
ab
amino
coupl
kit
ge
healthcar
interact
sp
rbd
genscript
china
detect
use
kinet
analysisconcentr
seriesdirect
bind
mode
flow
rate
set
bind
time
dissoci
time
min
result
analyz
biaevalu
softwar
determin
affin
constant
coip
assay
perform
use
pierc
coimmunoprecipit
kit
thermo
fisher
scientif
usa
accord
manufactur
protocol
antibodi
produc
laboratori
spike
antibodi
sino
biolog
china
use
antibodi
immobil
coip
elut
protein
detect
western
blot
boil
minut
elut
protein
load
sdspage
gel
transfer
pvdf
authorfund
right
reserv
reus
allow
without
permiss
copyright
holder
preprint
peerreview
http
doi
biorxiv
preprint
membran
millipor
boston
usa
block
nonfat
milk
hour
membran
incub
correspond
primari
antibodi
produc
laboratori
dilut
spike
antibodi
sino
biolog
china
dilut
c
overnight
imag
develop
incub
secondari
antibodi
goat
antimous
igg
hl
antibodi
thermo
fisher
scientif
usa
dilut
goat
antirabbit
igg
hl
antibodi
thermo
fisher
scientif
usa
dilut
room
temperatur
hour
elisa
assay
perform
identifi
interact
sp
hissp
rbd
protein
coat
micropl
incub
differ
concentr
protein
dilut
hour
wash
pbst
sampl
incub
antibodi
produc
laboratori
hour
incub
horseradish
peroxidas
hrp
label
goat
antimous
antibodi
hour
color
od
valu
nm
measur
fullwavelength
micropl
reader
epoch
biotek
instrument
inc
abil
meplazumab
compet
sp
bind
perform
competit
inhibit
elisa
protein
coat
onto
well
micropl
mixtur
hissp
rbd
meplazumab
dilut
ad
incub
subsequ
sampl
incub
spike
antibodi
sino
biolog
china
detect
hrplabel
goat
antirabbit
antibodi
hour
follow
step
similar
describ
earlier
vero
cell
infect
harvest
treat
fix
section
cell
prepar
dehydr
embed
wash
ultrapur
water
section
treat
h
min
block
goat
serum
section
incub
correspond
primari
antibodi
produc
laboratori
dilut
spike
antibodi
sino
biolog
china
dilut
hour
c
overnight
subsequ
section
wash
pb
min
treat
pb
contain
bovin
serum
albumin
bsa
ph
min
gold
colloidlabel
method
use
determin
local
sp
room
temperatur
section
consecut
stain
uranium
acet
lead
acet
immuneelectron
microscop
use
observ
protein
locat
